Replies to post #79182 on Biotech Values

[DewDiligence]

MNTA: I'm assuming $35 on approval or $4-5 on another setback.

Using your own numbers, investors are getting 5:1 odds at the current share price. Thus, you should be a buyer if you think approval is at least a 17% proposition.